4 Rules for Illustrating Ustekinumab's IL-12/IL-23 Dual Targeting
Visualizing the Mechanism of Action (MoA) for monoclonal antibodies is one of the most effective ways to engage, educate, and inspire a medical audience. Because drugs like ustekinumab operate on a complex molecular level, static text is often insufficient for explaining how they interrupt chronic inflammation.
At RxSlides, we use storytelling for science to ensure every animation reflects scientific precision and clarity. Here are four essential rules for illustrating ustekinumab's dual-targeting power in your next medical presentation.
Before explaining what the drug does, you must visualize what it is. Monoclonal antibodies are categorized by their origin, which dictates their clinical profile.
• Best Practice: Use a comparative layout to show the progression from murine (0% human) to fully human (100% human) antibodies.
• The Visualization: Your slides should emphasize that ustekinumab is a fully human monoclonal antibody. Visualizing this with a 100% human label within the antibody structure helps establish its high clinical advantage.
Ustekinumab is unique because of its dual targeting mechanism. Unlike drugs that target a single cytokine, ustekinumab intercepts two distinct molecular signals.
• Best Practice: Illustrate the cellular interaction by positioning the drug above the cell membrane.
• The Visualization: Use medically accurate animations to show the antibody blocking both IL-12 and IL-23 molecular targets simultaneously. This effectively communicates how the drug stops the inflammatory cascade before it can activate receptors on the cell surface.
Because ustekinumab is used for diverse conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, your visuals must change the anatomical "stage" accordingly.
• Best Practice: Pair the mechanism with relevant anatomical icons—such as skin, hands, or intestines—to ground the pharmacology in clinical reality.
• The Visualization: For psoriasis, illustrate the antibody intercepting signals within skin tissue layers. For Crohn's or ulcerative colitis, zoom in on the inflamed intestinal walls to show the drug intercepting IL-12 and IL-23 within the gastrointestinal tract.
Data presentation is most impactful when it shows the ultimate goal of treatment: remission.
• Best Practice: Use efficacy bar charts to compare drug performance across different time points, such as Week 1 versus Week 4.
• The Visualization: Contrast an inflamed segment of the intestine with a zoomed-in view of a healthy, non-inflamed intestine to clearly illustrate the clinical outcome of successful therapy. Additionally, use side-by-side comparisons to present administration routes, such as subcutaneous injection versus intravenous infusion, ensuring the audience understands the practical delivery of the drug.
Conclusion
By following these rules defining the antibody type, mapping the dual-target mechanism, grounding the action in specific anatomy, and visualizing the path to remission, you transform a dense pharmacological review into a dynamic learning experience.
.avif)
.avif)
.avif)
.png)
